These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 30171052)

  • 21. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
    Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
    Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers.
    Chabanon RM; Pedrero M; Lefebvre C; Marabelle A; Soria JC; Postel-Vinay S
    Clin Cancer Res; 2016 Sep; 22(17):4309-21. PubMed ID: 27390348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.
    McNamara MG; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E
    Cancer Treat Rev; 2020 Sep; 89():102084. PubMed ID: 32738738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
    Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
    J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response.
    Weir WH; Mucha PJ; Kim WY
    Cell Rep Med; 2022 May; 3(5):100602. PubMed ID: 35584624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complementarity of DDR, nucleic acids and anti-tumour immunity.
    Kornepati AVR; Rogers CM; Sung P; Curiel TJ
    Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
    Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
    Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
    Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
    Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients.
    Xiong A; Nie W; Zhou Y; Li C; Gu K; Zhang D; Chen S; Wen F; Zhong H; Han B; Zhang X
    Front Immunol; 2021; 12():708558. PubMed ID: 34630387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
    You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
    Front Immunol; 2022; 13():871756. PubMed ID: 35990677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
    Nishino M; Ramaiya NH; Hatabu H; Hodi FS
    Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers for immune therapy in gastrointestinal cancers.
    Weinberg BA; Hameed R; Marshall JL
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
    Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
    Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.
    Conway JR; Kofman E; Mo SS; Elmarakeby H; Van Allen E
    Genome Med; 2018 Nov; 10(1):93. PubMed ID: 30497521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
    Gong J; Wang C; Lee PP; Chu P; Fakih M
    J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
    Gandara DR; Paul SM; Kowanetz M; Schleifman E; Zou W; Li Y; Rittmeyer A; Fehrenbacher L; Otto G; Malboeuf C; Lieber DS; Lipson D; Silterra J; Amler L; Riehl T; Cummings CA; Hegde PS; Sandler A; Ballinger M; Fabrizio D; Mok T; Shames DS
    Nat Med; 2018 Sep; 24(9):1441-1448. PubMed ID: 30082870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.